Clinical Trials

547 enrolled 19 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02595944 2026-03-19

ANVIL

903 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03244384 2026-03-19

AMBASSADOR

739 enrolled

Ureteral Neoplasms

NCT04579224 2026-03-19

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

184 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05092958 2026-03-19

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

654 enrolled

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT00217737 2026-03-18

Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

2,431 enrolled 13 charts

Colonic Neoplasms

NCT00310180 2026-03-18

TAILORx

10,273 enrolled 14 charts

Breast Neoplasms

NCT00569127 2026-03-18

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

427 enrolled 17 charts

EndocrineNET

Neuroendocrine Tumors

NCT00843882 2026-03-18

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Classical hematologyMyeloidOther hematologic neoplasm

247 enrolled 19 charts

Anemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT01167712 2026-03-18

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

692 enrolled 11 charts

Brenner Tumor, Fallopian Tube Neoplasms

NCT01272037 2026-03-18

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

5,018 enrolled 14 charts

Carcinoma, Intraductal, Noninfiltrating

NCT01575548 2026-03-18

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

129 enrolled 11 charts

Carcinoma, Renal Cell

NCT02166463 2026-03-18

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

600 enrolled 14 charts 1 FDA

Lymphoid

Ann Arbor Stage IIB Hodgkin Lymphoma

NCT02193282 2026-03-18

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

390 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02466971 2026-03-18

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

450 enrolled 11 charts

Uterine Cervical Neoplasms, Vaginal Neoplasms

NCT02506153 2026-03-18

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

1,301 enrolled 16 charts

Dermatologic

Melanoma

NCT02997228 2026-03-18

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

120 enrolled

Colorectal Neoplasms

NCT03233711 2026-03-18

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

344 enrolled

Anal Canal Carcinoma, Anus Neoplasms

NCT03375320 2026-03-18

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

298 enrolled 14 charts 1 FDA

EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT03701282 2026-03-18

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

720 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03775265 2026-03-18

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

475 enrolled

Urinary Bladder Neoplasms

NCT03793166 2026-03-18

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

1,175 enrolled

Carcinoma, Renal Cell, Lymphatic Metastasis

NCT03811002 2026-03-18

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

544 enrolled 29 charts

Lung Neoplasms

NCT03811015 2026-03-18

Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

636 enrolled

Head & Neck

Oropharyngeal Neoplasms

NCT03871257 2026-03-18

A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

165 enrolled

CNS

Neurofibromatosis 1

NCT03914625 2026-03-18

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

6,720 enrolled

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT04092283 2026-03-18

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

660 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04214067 2026-03-18

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

164 enrolled

Sarcoma

Carcinosarcoma

NCT04214262 2026-03-18

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

480 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02306161 2026-03-17

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

312 enrolled 14 charts

Sarcoma

Sarcoma, Ewing

NCT02567435 2026-03-17

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

325 enrolled 14 charts

Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

NCT02954874 2026-03-17

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

1,155 enrolled

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03055013 2026-03-17

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

819 enrolled 12 charts

Carcinoma, Renal Cell

NCT03914612 2026-03-17

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

813 enrolled 16 charts 1 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT02446600 2026-03-05

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

579 enrolled 17 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00433511 2026-03-03

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

4,994 enrolled 11 charts

Breast Adenocarcinoma

NCT00588770 2026-03-03

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

403 enrolled 10 charts

Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT00602641 2026-03-03

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

306 enrolled 12 charts

Plasma cell

Multiple Myeloma

NCT01274338 2026-02-18

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

1,673 enrolled 19 charts

Dermatologic

Melanoma

NCT02224781 2026-02-18

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

267 enrolled 8 charts

Dermatologic

Melanoma

NCT02912559 2026-02-02

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

712 enrolled

Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, DNA Repair-Deficiency Disorders

NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

1,052 enrolled 27 charts

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT02115282 2025-12-18

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

608 enrolled 18 charts

Breast Neoplasms

NCT03907488 2025-12-04

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

994 enrolled 11 charts

Lymphoid

Hodgkin Disease

NCT02112916 2025-12-01

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

847 enrolled 19 charts

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02003222 2025-11-28

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

488 enrolled 13 charts 1 FDA

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02048813 2025-11-28

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

529 enrolled 12 charts 2 FDA

Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01371981 2025-11-26

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Other hematologic neoplasmSarcoma

1,645 enrolled 32 charts

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT02883049 2025-11-26

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations